Treating moderate to severe psoriasis - best use of biologics (Q38174153)

30 August 2017

title

Treating moderate to severe psoriasis - best use of biologics (English)

1 reference

30 August 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Maeve Lynch

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Brian Kirby

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

27 December 2013

1 reference

Expert Review of Clinical Immunology

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

269-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

The risk of mortality in patients with psoriasis: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Adalimumab treatment for severe recalcitrant chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Challenges for synthesising data in a network of registries for systemic psoriasis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

How safe are anti-rheumatic drugs during pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Do tumor necrosis factor inhibitors cause malformations in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

IL-17 targeted therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.873701

10.1586/1744666X.2014.873701

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24372444%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference